Filing Details
- Accession Number:
- 0001019695-17-000025
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2017-09-06 12:47:44
- Reporting Period:
- 2017-09-05
- Accepted Time:
- 2017-09-06 11:47:44
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1019695 | Arqule Inc | ARQL | Pharmaceutical Preparations (2834) | 043221586 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1436861 | Paolo Pucci | C/O Arqule, Inc. 1 Wall Street, 6Th Floor Burlington MA 01803 | Chief Executive Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2017-09-05 | 19,156 | $1.14 | 386,696 | No | 4 | P | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | P | Direct |
Footnotes
- Reflects the weighted average price as the shares were purchased in multiple transactions. The per share transaction price ranged from $1.13 to $1.15. The Reporting Person hereby undertakes to provide, upon request, by the U.S. Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.